JP2022122913A5 - - Google Patents

Download PDF

Info

Publication number
JP2022122913A5
JP2022122913A5 JP2022084419A JP2022084419A JP2022122913A5 JP 2022122913 A5 JP2022122913 A5 JP 2022122913A5 JP 2022084419 A JP2022084419 A JP 2022084419A JP 2022084419 A JP2022084419 A JP 2022084419A JP 2022122913 A5 JP2022122913 A5 JP 2022122913A5
Authority
JP
Japan
Prior art keywords
sequence
amino acid
tcr
acid residues
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022084419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022122913A (ja
JP7572399B2 (ja
Filing date
Publication date
Priority claimed from PCT/EP2017/058578 external-priority patent/WO2017174823A1/en
Application filed filed Critical
Publication of JP2022122913A publication Critical patent/JP2022122913A/ja
Publication of JP2022122913A5 publication Critical patent/JP2022122913A5/ja
Application granted granted Critical
Publication of JP7572399B2 publication Critical patent/JP7572399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022084419A 2016-04-08 2022-05-24 T細胞受容体 Active JP7572399B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1606156.6 2016-04-08
GB201606156 2016-04-08
PCT/EP2017/058578 WO2017174823A1 (en) 2016-04-08 2017-04-10 T cell receptors
JP2018552775A JP7204484B2 (ja) 2016-04-08 2017-04-10 T細胞受容体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018552775A Division JP7204484B2 (ja) 2016-04-08 2017-04-10 T細胞受容体

Publications (3)

Publication Number Publication Date
JP2022122913A JP2022122913A (ja) 2022-08-23
JP2022122913A5 true JP2022122913A5 (cg-RX-API-DMAC7.html) 2023-04-07
JP7572399B2 JP7572399B2 (ja) 2024-10-23

Family

ID=58536983

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018552775A Active JP7204484B2 (ja) 2016-04-08 2017-04-10 T細胞受容体
JP2022084419A Active JP7572399B2 (ja) 2016-04-08 2022-05-24 T細胞受容体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018552775A Active JP7204484B2 (ja) 2016-04-08 2017-04-10 T細胞受容体

Country Status (15)

Country Link
US (3) US20190144521A1 (cg-RX-API-DMAC7.html)
EP (2) EP3925972A1 (cg-RX-API-DMAC7.html)
JP (2) JP7204484B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190065189A (cg-RX-API-DMAC7.html)
CN (2) CN116239669A (cg-RX-API-DMAC7.html)
AU (2) AU2017248121B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018070637A2 (cg-RX-API-DMAC7.html)
CA (1) CA3020555A1 (cg-RX-API-DMAC7.html)
ES (1) ES2788188T5 (cg-RX-API-DMAC7.html)
IL (1) IL262124A (cg-RX-API-DMAC7.html)
MX (1) MX389173B (cg-RX-API-DMAC7.html)
RU (1) RU2018138837A (cg-RX-API-DMAC7.html)
SG (1) SG11201808750PA (cg-RX-API-DMAC7.html)
WO (1) WO2017174823A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201806862B (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA50819A (fr) 2014-12-23 2021-04-07 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MX2018012265A (es) * 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
KR20190065189A (ko) * 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체
MX395611B (es) 2016-04-08 2025-03-25 Adaptimmune Ltd Receptores de celulas t.
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
JPWO2019151392A1 (ja) * 2018-01-31 2021-02-04 国立大学法人東北大学 抗原特異的mhc発現調節法
KR102892744B1 (ko) * 2018-04-19 2025-11-28 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Mage-b2 특이성을 갖는 t 세포 수용체 및 이의 용도
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
CN110172091B (zh) * 2019-04-28 2020-04-03 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
MX2021015946A (es) * 2019-06-18 2022-04-18 Regeneron Pharma Receptores de linfocitos t de mage-a4 y métodos de uso de estos.
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
CN114555791B (zh) 2019-08-13 2026-07-14 伦敦国王学院 Il-1超家族时空限制性活性细胞因子铠装的免疫应答细胞
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
WO2021236638A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
CN111647069B (zh) * 2020-06-17 2022-06-21 深圳豪石生物科技有限公司 一种改进的tcr及其应用
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022140321A2 (en) * 2020-12-22 2022-06-30 Amgen Inc. Mage-b2-specific t-cell receptors
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术(广东)有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN117106060A (zh) * 2022-05-17 2023-11-24 香雪生命科学技术(广东)有限公司 一种识别mage的高亲和力t细胞受体及其应用
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
EP4750807A1 (en) * 2023-07-27 2026-06-03 Immatics Biotechnologies GmbH Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
EP4750806A1 (en) * 2023-07-27 2026-06-03 Immatics Biotechnologies GmbH Antigen binding proteins against mageb2
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596536B1 (en) * 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US6407063B1 (en) * 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
AU5992999A (en) 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
WO2010114129A1 (ja) * 2009-04-03 2010-10-07 国立大学法人愛媛大学 T細胞レセプター及び該レセプターをコードする核酸
US10024868B2 (en) 2009-06-09 2018-07-17 Vaxon Biotech Identification, optimization and use of shared HLA-B*0702 epitopes for immunotherapy
ES2635335T3 (es) 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
SG11201400521PA (en) * 2011-10-14 2014-08-28 Teva Pharmaceuticals Australia Pty Ltd ANTIBODIES TO CD1d
CA2912389C (en) * 2013-06-10 2020-01-28 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for reducing immunosupression by tumor cells
JP6255360B2 (ja) * 2015-03-04 2017-12-27 ヴァクソン バイオテックVaxon Biotech 共有hla−b*0702エピトープの同定、最適化および免疫療法のための使用
MX395611B (es) 2016-04-08 2025-03-25 Adaptimmune Ltd Receptores de celulas t.
IL308831A (en) 2016-04-08 2024-01-01 Immunocore Ltd T cell receptors
MX2018012265A (es) * 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
KR20190065189A (ko) * 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체

Similar Documents

Publication Publication Date Title
JP2023081949A5 (cg-RX-API-DMAC7.html)
JP2022153399A5 (cg-RX-API-DMAC7.html)
JP2020127406A5 (cg-RX-API-DMAC7.html)
CN111148756B (zh) T细胞受体
JP2022502056A5 (cg-RX-API-DMAC7.html)
RU2018138837A (ru) Т-клеточные рецепторы
HRP20221021T1 (hr) T stanični receptori specifični za kompleks tumorskog antigena ny-eso-1 sa hla-a*02
EP2760886B1 (en) Immunocytokine combination therapy
JP2017533698A5 (cg-RX-API-DMAC7.html)
RU2018138836A (ru) Т-клеточные рецепторы
IL262128B1 (en) T cell receptors
HRP20190472T4 (hr) Klaudin-6 specifični imunoreceptori i t-stanični epitopi
JP2019511222A5 (cg-RX-API-DMAC7.html)
RU2007101039A (ru) Иммуностимулирующие олигонуклеотидные мультимеры
JP2022513420A5 (cg-RX-API-DMAC7.html)
JP2013518123A (ja) Dll4アンタゴニストによる糖尿病の治療法
JP2022554395A5 (cg-RX-API-DMAC7.html)
JP2021531834A5 (cg-RX-API-DMAC7.html)
JP2024540275A5 (cg-RX-API-DMAC7.html)
JP2021525068A5 (cg-RX-API-DMAC7.html)
JP2021525067A5 (cg-RX-API-DMAC7.html)
CA2480996C (fr) Peptides derives ou provenant de cytokine et leur application en therapeutique
JP2022502078A5 (cg-RX-API-DMAC7.html)
CN110520534A (zh) 程序性死亡配体1的肠表达
JP2022547809A5 (cg-RX-API-DMAC7.html)